Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

APPY 1.43 +0.01 (0.70%)
price chart
Venaxis, Inc. (APPY) Presents APPY1 Test Data at ACEP14
Venaxis, Inc. (NASDAQ: APPY) announced the company's pivotal APPY1 Test clinical trial data were presented at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14).
Venaxis' APPY1 Trial Results Presented by Dr. David S. Huckins, M.D., at ...  MarketWatch
Related articles »  
Venaxis: Latest Clinical Data Reveals Huge Market Potential (APPY)
Venaxis Inc. recently reported detailed data of the clinical pathways undertaken by the pediatric patients enrolled in their pivotal trial.
Venaxis Inc (APPY) news: What Every Investor Needs To Know About Venaxis, Inc.
If we were Venaxis, Inc., how would we stage this cutoff? Considering appendicitis is dangerous if left unchecked, it is obvious that we want to minimize the number of people with appendicitis who can potentially slip through this cutoff.
Venaxis to Present at Canaccord Genuity 2014 Medical Technologies ...
CASTLE ROCK, Colo., Nov. 13, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1� Test, a rapid blood test for aiding in identifying children ...
Related articles »  
UPDATE: Aegis Capital Lowers PT on Venaxis Following Recent Dilution
In the report, Aegis Capital noted, �We are reducing our price target on Venaxis, Inc. due to the dilution that occurred in the wake of the firm's most recently-completed financing.
Venaxis Inc (APPY): Increase In Institutional Ownership, Q4 Catalyst Make ...  Seeking Alpha
Aegis Maintains Venaxis (APPY) at Buy, Cuts PT to $3.50 Following Recent ...  StreetInsider.com (subscription)
Related articles »  
Venaxis Announces Regulatory and Market Development Progress
11, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1� Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and ...
FDA wants more details on Venaxis' new ER diagnostic technology  Denver Business Journal (blog)
Related articles »  
Biota Pharmaceuticals Inc. And Venaxis Inc.: 2 Upcoming Biopharmaceuticals ...
Venaxis (NASDAQ:APPY) is a diagnostic company focused on developing and commercializing its unique multi-biomarker diagnostic test.
Venaxis Inc (APPY) news: Venaxis's Pivotal Data Due In March
(Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap.
Related articles »  
Venaxis Inc (APPY) news: Venaxis: A Potentially Bright Future And An Interview ...
There have been a number of articles written about Venaxis, Inc. (APPY) by other authors here on Seeking Alpha, and I would urge all readers to check all of them out, including the company website.
Related articles »  
Venaxis Inc (APPY) news: Venaxis expects APPY1 approval following positive ...
Venaxis' (APPY) APPY1 Test for identifying patients who are at low risk of appendicitis performed well in a pivotal trial, with sensitivity and negative predictive value results surpassing those in a pilot study.